EBNA1 may prolong G2/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs

Biochemical and Biophysical Research Communications

Volumn 307, Issue 3, 2003, Pages 653-659

  Chuang, Tzu Chao ^a,b   Lee, Yi Jen ^a   Liu, Jah Yao ^c   Lin, Yen Shing ^a   Li, Jhy Wei ^a,d   Wang, Vinchi ^a,e   Law, Sai Lung ^f   Kao, Ming Ching ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b FOOYIN UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE UNIVERSITY   (Taiwan)

^d Department of Physical Therapy and Rehabilitation Rehabilitation Assistive Device Center Da Chien General Hospital   (Taiwan)

^e CARDINAL TIEN HOSPITAL   (Taiwan)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

EBNA1; HER2 neu; Ovarian cancer; Tumorigenicity

Indexed keywords

ANTINEOPLASTIC AGENT; CELL NUCLEUS ANTIGEN; CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 1; ETOPOSIDE; PACLITAXEL; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DRUG SENSITIZATION; DRUG TARGETING; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

HUMAN HERPESVIRUS 4;

EID: 0042170407     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)01235-X     Document Type: Article

References (33)

1. Reese D.M., Slamon D.J. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells. 15:1997;1-8.
2. Lee K.F., Simon H., Chen H., Bastes B., Hung M.C., Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 378:1995;394-398.
3. Marchionni M.A. Cell-cell signalling neu tack on neuregulin. Nature. 378:1995;334-335.
4. Yu D., Hung M.C. Therapeutic resistance of erbB-2-overexpressing cancer and strategies to overcome this resistance. Ehrlich M. DNA Alterations in Cancer. 2001;457-470 Eaton Publishing, Natick, MA.
5. Slamon D.J., Godophin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., McGuire W.L. Studies of the Her2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
6. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., Soper J.T., Dodge R., Clarke-Pearson D.L., Marks P., McKenzie S., Yin S., Bast R.C. Jr. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:1990;4087-4091.
7. Yu D., Wolf J.K., Scanlon M., Price J.E., Hung M.C. Enhanced c-rebB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 53:1993;891-898.
8. Yu D., Wang S.S., Dulski K.M., Tsai C.M., Nicolson G.L., Hung M.C. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res. 54:1994;3260-3266.
9. Meden H., Marx D., Roegglen T., Schauer A., Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int. J. Gynecol. Pathol. 17:1998;61-65.
10. Pegram M.D., Finn R.S., Arzoo K., Beryt M., Pietras R.J., Slamon D.J. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene. 15:1997;5276-5282.
11. Tsai T.C., Yu D., Chang K.T., Wu L.H., Perng R.P., Ibrahim N.K., Hung M.C. Enhanced chemoresistance by elevation of p185neu level in HER2/neu-transfected human lung cancer cells. J. Natl. Cancer Inst. 87:1995;682-684.
12. Yu D., Liu B., Tan M., Li J., Wang S.S., Hung M.C. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 13:1996;1359-1365.
13. Yu D., Suen T.C., Yan D.H., Chang L.S., Hung M.C. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc. Natl. Acad. Sci. USA. 87:1990;4450-4499.
14. Matin A., Hung M.C. Negative regulation of the neu promoter by the SV40 large T antigen. Cell Growth Differ. 4:1993;1051-1056.
15. Kao M.C., Liu G.Y., Chuang T.C., Lin Y.S., Wuu J.A., Law S.L. The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene. Oncogene. 16:1998;547-554.
16. Lefvkowitz G., Oved S., Klapper L.N., Harari D., Lavi S., Sela M., Yarden Y. c-Cbl is a suppressor of the neu oncogene. J. Biol. Chem. 275:2000;33539-35532.
17. Xing X., Wang S.C., Zou Y., Xia X.Y., Shao R., Kwong K.Y., Yu Z., Zhang S., Miller S., Huang L., Hung M.C. The Ets protein PEA3 suppresses HER2/neu overexpression and inhibits tumorigenesis. Nat. Med. 6:2000;189-195.
18. Chuang T.C., Way T.D., Lin Y.S., Law S.L., Kao M.C. The Epstein-Barr virus nuclear antigen-1 may act as a transforming suppressor of the HER2/neu oncogene. FEBS Lett. 532:2002;135-142.
19. Sugden B., Warren N. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J. Virol. 63:1989;2644-2649.
20. Wilson J.B., Levine A.J. The oncogenic potential of Epstein-Barr virus nuclear antigen 1 in transgenic mice. Curr. Top. Microbiol. Immunol. 182:1992;375-384.
21. Loveland B.E., Johns T.G., Mackay I.R., Vaillant F., Wang Z.X., Hertzog P.J. Validation of the MTT dye assay for enumeration of cells in proliferative and antiproliferative assays. Biochem. Int. 27:1992;501-510.
22. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139:1991;271-279.
23. Ueno N.T., Yu D., Hung M.C. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene. 15:1997;953-960.
24. Schiff P.B., Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA. 77:1980;1561-1565.
25. Woods C.M., Zhu J., McQueney P.A., Bollag D., Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol. Med. 1:1995;506-526.
26. Tishler R.B., Lamppu D.M., Park S., Price B.D. Microtubule-active drugs Taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res. 55:1995;6021-6025.
27. Blagosklonny M.V., Schulte T., Nguyen P., Trepel J., Neckers L.M. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res. 56:1996;1851-1854.
28. Yu D., Jing T., Liu B., Yao J., Tan M., McDonnell T.J., Hung M.C. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol. Cell. 2:1998;581-591.
29. Ueno N.T., Bartholomeusz C., Herrmann J.L., Estrov Z., Shao R., Andreeff M., Price J., Paul R.W., Anklesaria P., Yu D., Hung M.C. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin. Cancer Res. 6:2000;250-259.
30. Zhou Z., Jia S.F., Hung M.C., Kleinerman E.S. E1A Sensitizes HER2/neu-overexpressing Ewing's Sarcoma cells to Topoisomerase II-targeting anticancer drugs. Cancer Res. 61:2001;3394-3398.
31. Zhou Z., Zwelling L.A., Kawakami Y., An T., Kobayashi K., Herzog C., Kleinerman E.S. Adenovirus-mediated human topoisomerase II-α gene transfer increases sensitivity of etoposide-resistant human breast cancer cells. Cancer Res. 59:1999;4618-4624.
32. Taylor W.R., Stark G.R. Regulation of the G2/M transition by p53. Oncogene. 20:2001;1803-1815.
33. Yaginuma Y., Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res. 52:1992;4196-4199.